These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 22699287)

  • 1. Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes.
    Cavelti-Weder C; Babians-Brunner A; Keller C; Stahel MA; Kurz-Levin M; Zayed H; Solinger AM; Mandrup-Poulsen T; Dinarello CA; Donath MY
    Diabetes Care; 2012 Aug; 35(8):1654-62. PubMed ID: 22699287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic and pharmacodynamic characteristics of single-dose Canakinumab in patients with type 2 diabetes mellitus.
    Noe A; Howard C; Thuren T; Taylor A; Skerjanec A
    Clin Ther; 2014 Nov; 36(11):1625-37. PubMed ID: 25240532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1β antibody, in patients with type 2 diabetes.
    Sloan-Lancaster J; Abu-Raddad E; Polzer J; Miller JW; Scherer JC; De Gaetano A; Berg JK; Landschulz WH
    Diabetes Care; 2013 Aug; 36(8):2239-46. PubMed ID: 23514733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gevokizumab in type 1 diabetes mellitus: extreme remedies for extreme diseases?
    Pafili K; Papanas N; Maltezos E
    Expert Opin Investig Drugs; 2014 Sep; 23(9):1277-84. PubMed ID: 25079039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of interleukin-1β antibody (canakinumab) on glycaemic indicators in patients with type 2 diabetes mellitus: results of secondary endpoints from a randomized, placebo-controlled trial.
    Hensen J; Howard CP; Walter V; Thuren T
    Diabetes Metab; 2013 Dec; 39(6):524-31. PubMed ID: 24075453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single and multiple ascending-dose study of glucagon-receptor antagonist RN909 in type 2 diabetes: a phase 1, randomized, double-blind, placebo-controlled trial.
    Gumbiner B; Esteves B; Dell V; Joh T; Garzone PD; Forgie A; Udata C
    Endocrine; 2018 Nov; 62(2):371-380. PubMed ID: 30203123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial.
    Sherry N; Hagopian W; Ludvigsson J; Jain SM; Wahlen J; Ferry RJ; Bode B; Aronoff S; Holland C; Carlin D; King KL; Wilder RL; Pillemer S; Bonvini E; Johnson S; Stein KE; Koenig S; Herold KC; Daifotis AG;
    Lancet; 2011 Aug; 378(9790):487-97. PubMed ID: 21719095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastrointestinal Therapeutic System Study Group.
    Simonson DC; Kourides IA; Feinglos M; Shamoon H; Fischette CT
    Diabetes Care; 1997 Apr; 20(4):597-606. PubMed ID: 9096986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic efficacy and safety of once-daily pioglitazone monotherapy in patients with type 2 diabetes: a double-blind, placebo-controlled study.
    Scherbaum WA; Göke B;
    Horm Metab Res; 2002 Oct; 34(10):589-95. PubMed ID: 12439788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-1-receptor antagonist in type 2 diabetes mellitus.
    Larsen CM; Faulenbach M; Vaag A; Vølund A; Ehses JA; Seifert B; Mandrup-Poulsen T; Donath MY
    N Engl J Med; 2007 Apr; 356(15):1517-26. PubMed ID: 17429083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gevokizumab in the Treatment of Autoimmune Non-necrotizing Anterior Scleritis: Results of a Phase I/II Clinical Trial.
    Knickelbein JE; Tucker WR; Bhatt N; Armbrust K; Valent D; Obiyor D; Nussenblatt RB; Sen HN
    Am J Ophthalmol; 2016 Dec; 172():104-110. PubMed ID: 27663070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin].
    Wilding JP; Woo V; Soler NG; Pahor A; Sugg J; Rohwedder K; Parikh S;
    Dtsch Med Wochenschr; 2013 Apr; 138 Suppl 1():S27-38. PubMed ID: 23529568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of Gevokizumab in Patients with Behçet's Disease Uveitis: An International, Randomized, Double-Masked, Placebo-Controlled Study and Open-Label Extension Study.
    Tugal-Tutkun I; Pavesio C; De Cordoue A; Bernard-Poenaru O; Gül A
    Ocul Immunol Inflamm; 2018; 26(7):1023-1033. PubMed ID: 29370572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus.
    Seino Y; Nakajima H; Miyahara H; Kurita T; Bush MA; Yang F; Stewart MW
    Curr Med Res Opin; 2009 Dec; 25(12):3049-57. PubMed ID: 19863477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial.
    Ridker PM; Howard CP; Walter V; Everett B; Libby P; Hensen J; Thuren T;
    Circulation; 2012 Dec; 126(23):2739-48. PubMed ID: 23129601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acarbose in ambulatory treatment of non-insulin-dependent diabetes mellitus associated to imminent sulfonylurea failure: a randomised-multicentric trial in primary health-care. Diabetes and Acarbose Research Group.
    Costa B; Piñol C
    Diabetes Res Clin Pract; 1997 Oct; 38(1):33-40. PubMed ID: 9347244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Gevokizumab on Interleukin-1β-Mediated Cytochrome P450 3A4 and Drug Transporter Repression in Cultured Human Hepatocytes.
    Moreau A; Le Vée M; Jouan E; Denizot C; Parmentier Y; Fardel O
    Eur J Drug Metab Pharmacokinet; 2017 Oct; 42(5):871-878. PubMed ID: 28260174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus.
    Herz M; Johns D; Reviriego J; Grossman LD; Godin C; Duran S; Hawkins F; Lochnan H; Escobar-Jiménez F; Hardin PA; Konkoy CS; Tan MH
    Clin Ther; 2003 Apr; 25(4):1074-95. PubMed ID: 12809958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of initiating insulin and metformin on glycemic control and inflammatory biomarkers among patients with type 2 diabetes: the LANCET randomized trial.
    Pradhan AD; Everett BM; Cook NR; Rifai N; Ridker PM
    JAMA; 2009 Sep; 302(11):1186-94. PubMed ID: 19755697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes.
    Matthews JE; Stewart MW; De Boever EH; Dobbins RL; Hodge RJ; Walker SE; Holland MC; Bush MA;
    J Clin Endocrinol Metab; 2008 Dec; 93(12):4810-7. PubMed ID: 18812476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.